Ligand Pharmaceuticals | LGND - Current Assets


Ligand Pharmaceuticals reported $832.27M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Agenus USD 133.95M 120.61M Sep/2025
Amgen USD 29.06B 1.17B Dec/2025
Anika Therapeutics USD 101.59M 2.27M Sep/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
Baxter International USD 6.87B 61M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Enviri Corporation USD 720.68M 48.56M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
Heron Therapeutics USD 238.07M 8.67M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Karyopharm Therapeutics USD 89.75M 8.12M Sep/2025
Ligand Pharmaceuticals USD 832.27M 78.35M Dec/2025
MacroGenics USD 232.09M 27.15M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Pacira USD 547.97M 14.78M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Veracyte USD 488.38M 39.15M Dec/2025